Showing 1851-1860 of 1951 results for "".
- Analysis: Ustekinumab, IL-23 Inhibitors Show Higher Drug Survival in Psoriasishttps://practicaldermatology.com/news/analysis-ustekinumab-il-23-inhibitors-show-higher-drug-survival-in-psoriasis/2485295/A new Danish cohort study using data from the DERMBIO registry suggests ustekinumab was linked with the best 5-year survival of comparators in bionaive patients with psoriasis. The analysis included a total of 7,193 treatment
- Contact Dermatitis, Unlabeled Ingredients Among Concerns in Self-Tannershttps://practicaldermatology.com/news/contact-dermatitis-unlabeled-ingredients-among-concerns-in-self-tanners/2485034/A recent review in the Journal of Drugs in Dermatology raised some concerns regarding ingredient safety and adverse reactions. Researchers on the study analyzed the top 50 best-selling sunless tanning products on Amazon
- AAD/NPF Guidelines Address Pediatric PsOhttps://practicaldermatology.com/news/aadnpf-guidelines-address-pediatric-pso/2460234/New guidelines from the American Academy of Dermatology and the National Psoriasis Foundation offer counsel on how to best manage psoriasis and its extracutaneous manifestations in children and adolescents. The 2019 guidelines of care for the management and treatment of psoriasis i
- Two New Psoriasis Guidelines Address Comorbidities, Biologic Treatmenthttps://practicaldermatology.com/news/two-new-psoriasis-guidelines-address-comorbidities-biologic-treatment/2459901/The American Academy of Dermatology and the National Psoriasis Foundation have released two new guidelines outlining best practices for treating psoriasis with a focus on comorbidities and biologic treatment. Develo
- Cutera: 20 Years, 20 Productshttps://practicaldermatology.com/news/cutera-20-years-20-products/2457802/Cutera, Inc. is celebrating 20 years of best-in-class product innovation with continued commitment to the industry and its providers, marking the milestone at the Annual Meeting of the American Society for Laser Medicine and Surgery in Dallas. In conjunction with the 20
- Asian Acne Board and Galderma Join Forces to Improve Understanding and Management of Acnehttps://practicaldermatology.com/news/asian-acne-board-and-galderma-join-forces-to-improve-understanding-and-management-of-acne/2458799/The Asian Acne Board (AAB) and Galderma are inviting candidates to apply for a research grant of $10,000 to contribute to the improvement of best practices in the management of acne. The AAB research grant with the unrestricted support of Galderma is focused on advancing the understa
- Dermatology Resident Survey Finds Practice Gaps in Patient Safetyhttps://practicaldermatology.com/news/20140417-dermatology_resident_survey_finds_practice_gaps_in_patient_safety/2459267/A 2012 survey-based study of 142 dermatology residents from 44 US and Canadian residency programs was conducted to identify the source of clinical practices among dermatology residents that affect patient safety and determine the best approach for overcomi
- CellCeuticals Nominated for Cosmetic Innovation Awardhttps://practicaldermatology.com/news/20120629-cellceuticals_nominated_for_cosmetic_innovation_award/2459777/CellCeuticals Skin Care, Inc., Biomedical Skin Treatments was named a finalist in two categories by the Independent Cosmetic Manufacturers and Distributors Association (ICMAD). InterActive Moisture Serum 2 was nominated for Best Skin Care P
- Biologics, JAKs, and More Cited as Potential Treatments for CPUOhttps://practicaldermatology.com/news/Biologics-JAKis-More-Cited-Potential-Treatments-CPUO/2471552/New therapies for chronic pruritus of unknown origin (CPUO) could be close, Gil Yosipovitch, MD, said during his presentation, “What’s Best and What’s Next for Systemic Itch and CPUO” at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. “These are patients
- Dr. Lain Discusses Predictive Modeling for PsO Biologic Selectionhttps://practicaldermatology.com/news/Dr-Lain-Discusses-Predictive-Modeling-PsO-Biologic-Selection/2471252/Edward (Ted) Lain, MD, MBA, reminded attendees at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii, that a method exists for selecting the best class of biologic for each psoriasis patient. “I just want to keep this in the public conscience here,” Dr. Lain said. “There i